IONS Quote, Financials, Valuation and Earnings

Biogen has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 10.87%. Ionis Pharmaceuticals's return on equity of -103.27% beat Biogen's return on equity of 10.33%.

Ionis Pharmaceuticals has a consensus price target of $59.42, signalling upside risk potential of 90.75%. On the other hand Biogen has an analysts' consensus of $200.12 which suggests that it could grow by 44.62%. Given that Ionis Pharmaceuticals has higher upside potential than Biogen, analysts believe Ionis Pharmaceuticals is more attractive than Biogen.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Biogen quarterly revenues of $2.5B. Ionis Pharmaceuticals's net income of -$104.3M is lower than Biogen's net income of $266.7M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biogen's PE ratio is 12.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.60x versus 2.09x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 16.72%. Ionis Pharmaceuticals's return on equity of -103.27% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Ionis Pharmaceuticals has a consensus price target of $59.42, signalling upside risk potential of 90.75%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.72 which suggests that it could grow by 35.39%. Given that Ionis Pharmaceuticals has higher upside potential than Biomarin Pharmaceutical, analysts believe Ionis Pharmaceuticals is more attractive than Biomarin Pharmaceutical.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 32.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.60x versus 4.97x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 39.44%. Ionis Pharmaceuticals's return on equity of -103.27% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Ionis Pharmaceuticals has a consensus price target of $59.42, signalling upside risk potential of 90.75%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 37.2%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.836, suggesting its less volatile than the S&P 500 by 16.449%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 18.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.60x versus 6.27x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of -80.9%. Ionis Pharmaceuticals's return on equity of -103.27% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Ionis Pharmaceuticals has a consensus price target of $59.42, signalling upside risk potential of 90.75%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $90.21 which suggests that it could grow by 138.53%. Given that Ultragenyx Pharmaceutical has higher upside potential than Ionis Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Ionis Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.17%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are larger than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Ionis Pharmaceuticals's net income of -$104.3M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.60x versus 6.11x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.